Citigroup Issues Pessimistic Forecast for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price target lowered by Citigroup from $2.75 to $1.75 in a research report issued on Friday,Benzinga reports. The firm presently has a “neutral” rating on the stock. Citigroup’s price objective would suggest a potential upside of 32.58% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. Cantor Fitzgerald dropped their target price on shares of Health Catalyst from $4.00 to $3.00 and set a “neutral” rating for the company in a report on Friday. Canaccord Genuity Group decreased their price target on Health Catalyst from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Friday. Raymond James Financial set a $3.00 price objective on Health Catalyst in a research report on Friday. Stifel Nicolaus dropped their price objective on Health Catalyst from $3.75 to $2.00 and set a “hold” rating for the company in a research note on Friday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Health Catalyst in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.16.

Health Catalyst Price Performance

NASDAQ HCAT opened at $1.32 on Friday. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.46. Health Catalyst has a 12 month low of $1.20 and a 12 month high of $5.06. The stock has a market cap of $93.36 million, a price-to-earnings ratio of -0.52 and a beta of 1.76. The company’s 50 day moving average is $2.05 and its two-hundred day moving average is $2.56.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Thursday, March 12th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.02). The firm had revenue of $74.68 million during the quarter, compared to the consensus estimate of $73.99 million. Health Catalyst had a negative return on equity of 3.98% and a negative net margin of 57.20%. As a group, research analysts anticipate that Health Catalyst will post -0.33 earnings per share for the current year.

Institutional Trading of Health Catalyst

Several hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC purchased a new position in shares of Health Catalyst during the fourth quarter valued at about $25,000. Pilgrim Partners Asia Pte Ltd purchased a new stake in shares of Health Catalyst in the third quarter worth about $39,000. Cresset Asset Management LLC purchased a new stake in shares of Health Catalyst in the second quarter worth about $39,000. FNY Investment Advisers LLC bought a new position in Health Catalyst during the third quarter valued at approximately $45,000. Finally, Focus Partners Wealth bought a new position in Health Catalyst during the first quarter valued at approximately $46,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Key Health Catalyst News

Here are the key news stories impacting Health Catalyst this week:

• Positive Sentiment: Revenue and some profitability metrics showed resilience: Q4 revenue slightly beat consensus ($74.68M vs. $73.99M) and the company reported full‑year revenue of $311.1M with Adjusted EBITDA of $41.4M — signals that core demand remains. Health Catalyst Reports Fourth Quarter and Year End 2025 Results
• Positive Sentiment: Some chart/analyst commentary suggests the stock may be finding technical support (hammer pattern) and that earnings‑estimate revisions could stabilize — a possible near‑term bottom for opportunistic buyers. HCAT May Find a Bottom Soon
• Neutral Sentiment: Management has launched a strategic review and the CEO would not rule out a potential sale — this could unlock value but also creates uncertainty around capital allocation and timing. Seeking Alpha: CEO declines to rule out sale
• Negative Sentiment: The quarter showed an EPS miss and continued negative margins — Q4 EPS missed estimates (reported ~$0.08 vs. consensus around $0.10), which undercut confidence in near‑term profitability. MarketBeat Q4 results summary
• Negative Sentiment: Q1 revenue guidance was lowered to $68.0M–$70.0M vs. consensus ~ $74.1M — the guidance shortfall appears to be the main driver of the selloff since it signals softer near‑term top‑line momentum. Earnings press release / guidance
• Negative Sentiment: Multiple sell‑side firms lowered price targets and moved to neutral/hold/equal‑weight (Citigroup to $1.75, Stephens and Stifel to $2.00), increasing downward pressure and reducing buy‑side conviction. Analyst price-target cuts (Benzinga)
• Negative Sentiment: Market reaction was amplified by heavy volume and headlines emphasizing the mixed print and management uncertainty, leading to sharp intraday selling despite the revenue beat. MSN: stock reaction

Health Catalyst Company Profile

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.